Egetis Therapeutics AB

Egetis has secured a green light in Europe for its ultra rare disease drug Emcitate and the Swedish biotech is looking to hit the ground running with a first launch in the next few months on its own.

Eli Lilly and Italfarmaco were due this week to appear before the European Medicines Agency’s human medicines committee, the CHMP, for oral explanations as to why their respective drugs, donanemab and

Seven orphan drugs including MSD ’s sotatercept, for pulmonary arterial hypertension (PAH), and Pfizer 's marstacimab, for patients with hemophilia, are among the latest products that have been file

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Menarini, SciClone Will Partner On